Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Leaders Outline Strategies for Survival in New Year's Addresses
January 24, 2005
- BULLETIN
January 24, 2005
- Aventis Pharma Aims to Strengthen Allegra's Leading Position
January 24, 2005
- BULLETIN
January 24, 2005
- NBI Is Aggressive to Defend Alesion's Leading Position
January 24, 2005
- PMDA to Rise with Ascending Current in FY2005: Mr Miyajima
January 24, 2005
- Niichiko Aiming for Sales of \24 Bil. This Fiscal Year
January 24, 2005
- To Do Utmost to Deal with Many Challenges: Mr Asonuma of the PFSB
January 24, 2005
- Meiji Seika Expects Pharma Sales of \111 Bil. in FY2004
January 24, 2005
- DIAGNOSTIC NEWS IN BRIEF
January 24, 2005
- New PAL to Accelerate Selection of Generic Companies: Mr Aratani of Taiyo Pharm
January 24, 2005
- Committees to Evaluate Efficacy of Drugs Questioned in EBM-based GL
January 24, 2005
- JPMA to Start Full-Scale Discussions on New Drug Pricing
January 24, 2005
- PMDA's Performance in 1st Half of FY2004 Announced
January 24, 2005
- BUSINESS NEWS IN BRIEF
January 24, 2005
- Designation of Prescription Drugs Proceeding as Planned: Korosho
January 24, 2005
- WEBSITE NEWS
January 24, 2005
- Full-scale Discussions on Revision of Medical Service Law to Begin in Autumn
January 24, 2005
- NEW PRODUCTS
January 24, 2005
- Opinions on Revisions of ADR, Malfunctions Reporting Criteria Sought: Korosho
January 24, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…